<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PEMETREXED</span><br/>(pe-me-trex'ed)<br/><span class="topboxtradename">Alimta<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">antimetabolite, antifolate</span><br/><b>Prototype: </b>Methotrexate<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Suppresses tumor growth by inhibiting both DNA synthesis and folate metabolism at multiple target enzymes.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Appears to arrest the cell cycle, thus inhibiting tumor growth. Some data suggest that pemetrexed may increase the effects
         of radiation therapy in cells sensitive to the drug.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of malignant pleural mesothelioma that is unresectable or in patients that are not surgery candidates in combination
         with cisplatin; treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Has been used investigationally in other solid tumors, including bladder, breast, colorectal, gastric, head and neck, pancreatic,
         and renal cell cancers.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Mannitol hypersensitivity; creatinine clearance is 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Anemia, thrombocytopenia, neutropenia, dental disease; older adults; hepatic disease, hypoalbuminemia, hypovolemia, dehydration,
         ascites, pleural effusion.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Malignant Mesothelioma, Non-Small Cell Lung Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 500 mg/m<sup>2</sup> on day 1 of each 21-d cycle<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Not recommended if Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Pre-/posttreatment with folic acid, vitamin B<sub>12</sub>, and dexamethasone are needed to reduce hematologic and gastrointestinal toxicity, and the possibility of severe cutaneous
                     reactions from pemetrexed.
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute each 500-mg vial with 20 mL of preservative-free NS. Do not use any other diluent. Swirl gently to dissolve.
                  Each vial will contain 25 mg/mL. Withdraw the needed amount of reconstituted solution and add to 100 mL of preservative-free
                  NS. Discard any unused portion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Do <small>NOT</small> give a bolus dose. Infuse over 10 min.  
               </p>
</td>
</tr>
</table>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">
<b>Solution/additive</b>
            				:</span> Solutions containing <b>calcium, Lactated Ringer's</b>
<b>.</b>
<span class="incompattype">
<b>Y-site</b>
            				:</span>
<b>Amphotericin B, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, chlorpromazine, ciprofloxacin, dobutamine, doxorubicin,
            doxycycline, droperidol, gemcitabine, gentamicin, irinotecan, metronidazole, minocycline, mitoxantrone, nalbuphine, ondansetron,
            prochlorperazine, tobramycin, topotecan.</b>
</p>
<ul>
<li>Store unopened single-use vials at room temperature between 15°30° C (59°86° F). The reconstituted
            drug is stable for up to 24 h at 2°8° C (36°46° F) or at 25° C (77° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fatigue, fever</span>
<i>,</i> hypersensitivity reaction, edema, myalgia, arthralgia. <span class="typehead">CNS:</span> Neuropathy, <span class="speceff-common">mood alteration, depression</span>. <span class="typehead">CV:</span> Chest pain, thromboembolism. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, constipation, anorexia, stomatitis, diarrhea</span>
<i>,</i> dehydration, dysphagia, esophagitis, odynophagia, increased LFTs. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Neutropenia, leukopenia, anemia, thrombocytopenia</span>. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Dyspnea.</span>
<span class="typehead">Skin:</span>
<span class="speceff-common">Rash, desquamation</span>
<i>,</i> alopecia. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Increases serum creatinine,</span> renal failure. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased risk of renal toxicity with other nephrotoxic drugs <b>(acyclovir, adefovir, amphotericin B,</b>
<span class="classification">aminoglycosides</span>, <b>carboplatin, cidofovir, cisplatin, cyclosporine, foscarnet, ganciclovir, sirolimus, tacrolimus, vancomycin);</b>
<span class="classification">nsaid</span>s may increase risk of renal toxicity in patients with preexisting renal insufficiency; may cause additive risk of bleeding
      with <span class="classification">anticoagulants, platelet inhibitors</span>, <b>aspirin,</b>
<span class="classification">thrombolytic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Not extensively metabolized. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 3.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician if the absolute neutrophil count (ANC) is 3 or the platelet count is less than at least 100,000 cells/mm<sup>3</sup>, or if the Cl<sub>cr</sub> is 
         </li><li>Lab tests: Baseline and periodic CBC with differential; monitor for nadir and recovery before each dose (on day 8 and 15,
            respectively, of each cycle); periodic LFTs, serum creatinine and BUN.
         </li>
<li>Notify physician for S&amp;S of neuropathy (paresthesia) or thromboembolism.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following to physician: symptoms of anemia (e.g., chest pain, unusual weakness or tiredness, fainting
            spells, lightheadedness, shortness of breath); symptoms of poor blood clotting (e.g., bruising; red spots on skin; black,
            tarry stools; blood in urine); symptoms of infection (e.g., fever or chills, cough, sore throat, pain or difficulty passing
            urine); symptoms of liver problems (e.g., yellowing of skin).
         </li>
<li>Do not take nonsteroidal antiinflammatory drugs (<small>NSAID</small>s) without first consulting the physician.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>